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elevation in lead VI. ST segment elevation in one (lead VI) or
more of the conventional right precordial leads in the presence of
acute left ventricular inferior myocardial infarction was found to
be highly suggestive of coexisting right ventricular infarction (I).
The recording of lead V4R may further enhance the ability of the
electrocardiogram to recognize this right ventricular lesion in pa-
tients who do not display the ST segment elevation in lead VI
(2,3). Since this helpful sign is readily available from a routine
test, it deserves full utilization.
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Reply
We thank Shah for calling our attention to a previous report
(I) of right to left shunt complicating inferior infarction,
Nikolic is correct in assessing the electrocardiographic rhythm
as accelerated junctional, probably with 4:3 retrograde and 2: I
antegrade conduction; thus the term "high degree atrioventricular
block" may be inappropriate in this setting. The tracing reveals
in addition ST depression in anterior precordial leads (more pro-
nounced in a subsequent tracing) accompanying inferior ST ele-
vation. This has been reported to suggest posterior involvement
(2). Thallium-20l myocardial scintigraphy at rest in this patient
revealed posterior and inferior perfusion defects; thus we did not
think it unreasonable to report this as inferoposterior infarction.
Chou, Fowler as well as Nikolic point out the importance of
ST elevation in right precordial leads as evidence of right ven-
tricular infarction. A recent report (3) has corroborated the high
sensitivity, specificity and predictive accuracy of this finding.
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Interaction of Calcium Channel and
Beta-Adrenergic Blocking Agents
The combined administration of verapamil and propranolol or other
beta-adrenergic blocking drugs is assuming increasing importance
in treating severe angina. Increasing use is likely to bring problems
due to drug interactions.
Winniford et al. (I) address this issue and note that the pro-
pranolol-verapamil combination was superior to propranolol alone.
The point is made that the combination should be used cautiously
because of potentially serious adverse effects, and the small in-
cidence of such effects in their study was, at least in part, related
to the exclusion from the study of patients with congestive heart
failure or overt conducting system disease (I). This is entirely
reasonable, as patients with these underlying problems are pre-
dictably prone to experience adverse effects of such a therapeutic
combination.
However, it is important to note that adverse interactions be-
tween verapamil and beta-adrenergic blocking drugs may occur
quite unpredictably in patients with relatively normal left ventric-
ular function and absence of conducting system disease, who would
not normally be expected to experience problems with such a
combination. Our recent report (2) describes a group of patients
with ischemic heart disease, no evidence of preexisting conducting
system disease or heart failure and normal or only mildly impaired
left ventricular function (assessed by subsequent cardiac catheter-
ization or radionuclide angiography) who developed a shocklike
syndrome with profound cardiac failure, hypotension and brady-
arrhythmias soon after institution of combined oral therapy with
verapamil and beta-adrenergic blocking drugs, and which resolved
with cessation of the combined therapy. Since the report was
submitted, we noted several additional patients under similar cir-
cumstances, with a variety of beta-adrenergic blocking drugs, in-
cluding propranolol.
Such reactions were not clearly verapamil dose-dependent and
no other factor apart from the addition of the second agent was
found to account for the dramatic clinical deterioration in these
patients and the subsequent improvement with termination of this
therapy. Therefore, left ventricular function at rest, even when
relatively preserved, and absence of overt conducting system dis-:
ease, do not provide an accurate guide to tolerance of this drug
combination.
Verapamil is an excellent antianginal agent with negative in-
otropic and chronotropic effects (3). Although its combination with
a beta-adrenergic blocking drug may be contraindicated in certain
obvious cases, this idiosyncratic, unpredictable adverse interaction
as described above in otherwise "good candidates" for the com-
bination is of some concern, and its incidence could well increase
as the use of verapamil becomes more widespread. In this light,
if the combination of a beta-adrenergic blocking drug and a calcium
channel blocker is contemplated, then perhaps it may be preferable
to use a less overtly negative inotropic and chronotropic calcium
channel blocker, such as diltiazem or nifedipine, with which no
such idiosyncratic effects have yet been noted.
VICTOR S. WAYNE, MD, FRACP
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Reply
Over the past 2 years we have cautiously combined the beta-adre-
nergic blocking agents and verapamil in selected patients without
congestive heart failure or marked left ventricular dysfunction, and
we have not observed the shocklike syndrome described by Wayne
et al. In our experience, the adverse effects of this drug combi-
nation are usually related to their combined negative chronotropic
effects, with resultant bradyarrhythmias. Although nifedipine may
be preferable in combination with a beta-blocker, serious adverse
reactions, including congestive heart failure and profound hypo-
tension, have been reported with a nifedipine-beta-blocker com-
bination (1-4). The safety of a diltiazem-beta-blocker combination
is unknown, but we would be concerned about the bradyarrhyth-
mias that might result from such a combination. For selected pa-
tients with limiting angina despite therapy with a beta-adrenergic
blocker, we believe the cautious addition of a calcium channel
blocker is warranted. Further controlled studies are needed to de-
fine the relative safety and efficacy of the three available calcium
antagonists in combination with a beta-adrenergic blocker.
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